Xcout IntelSign inSubscribe

ACRUX LIMITED competitors & alternatives

Pharmaceuticals, Biotechnology & Life SciencesWest Melbourne, Australia

The 12 closest competitors and alternatives to ACRUX LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what ACRUX LIMITED actually does, not by market-cap band.

12Competitors listed

Subscribe to see ACRUX LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About ACRUX LIMITED

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.

ACRUX LIMITED at a glance

ACRUX LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in West Melbourne, Australia. Xcout tracks 16 named people at ACRUX LIMITED, including John Warmbrunn (Managing Director & Chief Executive Officer).

ACRUX LIMITED leadership

  • John WarmbrunnManaging Director & Chief Executive Officer
  • Mark Steven FogelPresident, Chief Executive Officer & Director
  • Kyle K. BrengelChief Operating Officer
  • Eldron C. BlackwellChief Financial Officer & Senior Vice President
  • Jaclyn Alyce JesbergerChief Legal Officer, Senior Vice President & Secretary
  • Linda KilpatrickVice President, Chief Accounting Officer & Controller

10 more named people on record for ACRUX LIMITED, with roles, board committees and tenure — see the full roster →

Top 12 ACRUX LIMITED competitors

Ranked by semantic similarity — how close each company is to ACRUX LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

AROVELLA THERAPEUTICS LIMITEDALA · Pharmaceuticals, Biotechnology & Life SciencesPreston, Australia
67% matchPublic

Similar pharmaceuticals, biotechnology & life sciences company

Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.

Market cap$55.9M
Employees27
AROVELLA THERAPEUTICS LIMITED competitors & alternatives →
Organon & Co.OGN · PharmaceuticalsJersey City, United States
64% matchPublic

Pharmaceuticals

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.

Market cap$3.6B
Employees10,000
Organon & Co. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of ACRUX LIMITED and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for ACRUX LIMITEDand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →